We Offer Worldwide Shipping
Login Wishlist

Ezetimibe

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1035

  • Specification : 98%(HPLC)

  • CAS number : 163222-33-1

  • Formula : C24H21F2NO3

  • Molecular Weight : 409.43

  • PUBCHEM ID : 150311

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1035

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

409.43

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

C1=CC(=CC=C1C2C(C(=O)N2C3=CC=C(C=C3)F)CCC(C4=CC=C(C=C4)F)O)O

Synonyms

Ezetimide/Zetia/EzitiMibeEzetiMibeC24H21F2N03/Ezetrol/(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one/Int/(3R,4S)-1-(4-Fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone/ezetimibe/EzetiMib/(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one/(3R,4S)-1-(4-Fluorphenyl)-3-[(3S)-3-(4-fluorphenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-on/2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)-

IUPAC Name

Density

1.3±0.1 g/cm3

Solubility

Flash Point

349.9±31.5 °C

Boiling Point

654.9±55.0 °C at 760 mmHg

Melting Point

164-166a„ƒ

InChl

InChI=1S/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m1/s1

InChl Key

OLNTVTPDXPETLC-XPWALMASSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:163222-33-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28231943

KEYWORDS

acute coronary syndrome; ezetimibe; low-density lipoprotein cholesterol; risk stratification; secondary prevention; statin.

Title

Who Should Receive Ezetimibe?

Author

Gregory G Schwartz 1

Publish date

2017 Feb 28

PMID

26324293

Abstract

Patients who take statins frequently experience adverse events, typically muscle symptoms. Some of these patients develop statin intolerance and discontinue the statin treatment. The treatment of a statin intolerant patient can be difficult. Treatment possibilities include a low dose regimen of statin, possibly in combination with another lipid-lowering agent, most commonly ezetimibe.

Title

[Statin Intolerance]

Author

Christina Boesgaard Graversen 1, Mogens Lytken Larsen, Erik Berg Schmidt

Publish date

2015 Aug 31

PMID

25659868

Title

New Insights on Ezetimibe. Introduction

Author

Alberico L Catapano 1

Publish date

2015 Feb;


Description :

Empty ...